The molecular neutralizing effect of anti-RBD IgG against phages displaying delta ()-RBD (L452R + T478K) compared to D614G-RBD was analyzed in 16 serum samples from individuals vaccinated with the heterologous scheme. [7], The vaccine requires two doses, the second one being administered four weeks after the first shot. ANMAT/Argentina: 3 years of age and older. Phase I, II and II CECMED/Cuba: SOBERANA 02 and SOBERANA 02 ST: Two doses (0.5 mL each) 4 weeks apart. Instituto Finlay de Vacunas Cuba: Soberana 02. Neisseria meningitidis in 1989 in Cuba and Outcome: contracting severe COVID-19. The candidate vaccine induced high antibody titers against RBD and with the ability to inhibit the interaction of RBD with its receptor ACE2, as well as to neutralize the live virus. They have been observed more often after the second dose compared to the first dose, Safety data from vaccination in immunosuppressed people, including patients living with HIV and autoimmune diseases. sobre Leptospira, Fase I, II Soberana Plus and Soberana Plus ST: 4 months, Soberana 2 and Soberana Plus: Maximum 6 hours (2 to 8C) This paper reviews 20 years of experience and scientific contributions of the Cuban meningococcal BC vaccine (VA-MENGOC-BC) obtained by the Finlay Institute in Havana, Cuba. When a third dose of Soberana Plus was added to the treatment, the efficacy improved to 64.9% for prevention of symptomatic disease, 96.6% for prevention of severe disease, and 96.6% for prevention of hospitalisation. In 1965, the National Center for Scientific Research (CNIC) was inaugurated. The Dalian Institute of Chemical Physics (DICP). Son reconocidos los efectos de nuestras vacunas en el control de epidemias como la causada Preprint data show that a three-dose combo of Soberana jabs has 92.4% efficacy in clinical trials. The vaccine is known as PastoCovac ( Persian: ) in Iran, where it has been developed in collaboration with the Pasteur Institute of Iran. Results show that the candidate vaccine is safe. Which means that 714 people need to receive the vaccine for one of them to not contracting severe COVID-19. The director of Cuba's Finlay Institute of Vaccines, which developed the Soberana 2 vaccine, has said the country could produce 100 million doses by the end of the year, 70 million more than. Ministry of Health/Russian Federation: contraindicated in pregnant women. The aim of the study was to assess the efficacy and safety of two doses of Soberana 02 vaccine with a heterologous booster dose. Ages 12 to 15: 100% (75.3-100.0%) [, Recommended if the benefits of vaccination outweigh the potential risks [, Available data are insufficient to inform vaccine-associated risks in pregnancy [, Available data are insufficient to assess the vaccine-associated risks in pregnancy [, Vaccine effectiveness against COVID-19 declines as for six months after a primary series in the context of variants of concern (including Delta and Omicron variants)[, Vaccine effectiveness against COVID-19 declines as for six months after a primary series in the context of variants of concern (including Delta and Omicron variants [, Vaccine efficacy among ages 6 months through 5 years was evaluated during the, The vaccine efficacy in adults was assessed while, AstraZeneca/Oxford; SK BIO; Serum Institute of India COVID-19 vaccine: Vaxzevria; Covishield (EUL). Graphs are temporarily unavailable due to technical issues. see report of the Pan American Health Organization, PAHO SAGE/WHO: Three doses (3 g, 0.2 each), and two boosters (fourth and fifth doses) given 4-6 months after the previous dose. Se publican los resultados finales del Ensayo clnico Fase III de Soberana02. Multidose vials of 2, 8 or 10 doses (0.5 mL each). SAGE/WHO: Novavax COVID-19 vaccine combined with any other EUL COVID-19 vaccine is considered a complete primary series. 72% (63-79%) Multidose vial of 5 doses (0.5 mL each). [29], The roll-out began with an "Interventional Trial"[30] that consisted of inoculating 150,000 at-risk participants which seems to be defined as health-care workers. Ages 12 to 15: 100% (75-100%) [, Ongoing studies. SOBERANA 02 ST Authorized for emergency use on August 2021 [ CECMED, 2021 ]. There is no available data on interchangeability. CECMED/Cuba: Three doses (50 g, 0.5 mL) 2 weeks apart. Feeling of general malaise (5%)", "[Translated]In more than 62 thousand applied doses of #Soberana02 the safety of the vaccine has been demonstrated. The relative risk of contracting COVID-19 in the group that received the Finlay Institute COVID-19 vaccine versus the group that received the placebo vaccine was 0.29 (95% CI 0.2 to 0.41). Third Cuban Vaccine, Soberana Plus, Approved for Emergency Use To obtain SAGE/WHO: Three doses (3 g, 0.2 each). SAGE/WHO: Extended primary series with an additional (third) dose 1-3 months after the second dose, and two boosters (fourth and fifth doses) given 4-6 months after the previous dose. The first two doses administered 3 weeks apart, followed by a third dose 8 weeks after. Very rare cases of capillary leak syndrome (CLS) were reported in the first days after vaccination with Janssen COVID-19 vaccine, with fatal outcomes in some people with prior experience of CLS. fue erradicada con nuestro producto VA-MENGOC-BC, despus de una campaada de vacunacin. mVNT50 GMT of 962.9 (95% CI, 670.1-1384) against phages displaying D614G-RBD and 384.1 (95% CI, 262-562.9) against -RBD phages, meaning a reduction of 2.5-fold the molecular neutralization capacity of the antibodies. Delegation of Finlay Institute of Vaccines of Cuba arrives in Italy This medical article is a stub. The extended sequence includes two N-glycosylation sites at residues Asn331 and Asn343 and two O-glycosylation sites at Thr323 and Ser325. [Eugenia-Toledo-Roman M, 2022 ], Immunogenicity outcomesNo studies reported or assessed this outcome, Immunogenicity outcomesSoberana 01A was a phase 1 randomized trial conducted in Cuba. SAGE/WHO: Extended primary series with an additional (third) 30 g dose 1-3 months after the second dose, and two boosters (fourth and fifth doses) given 4-6 months after the previous dose. 3 Finlay Vaccine Institute, Atabey, Playa, Havana, Cuba. Instituto Finlay de Vacunas Cuba: Soberana 02 Guillain-Barr syndrome (GBS) have been reported very rarely following vaccination with Vaxzevria [21]. Cuba leads race for Latin American coronavirus vaccine | Reuters VE to prevent COVID-19 disease after heterologous booster dose was 94.3% (95% CI, 83.3% to 98.1%) for participants 19-64 years old and 70.4% (95% CI. [4] A third (booster) dose of Soberana Plus may also be given on day 56. interrogans (serovars) was also obtained EMA recommends that persons with a known history of CLS should not be vaccinated with Janssen COVID-19 vaccine [7] [18]. SAGE/WHO: Valneva COVID-19 vaccine may be used as a booster dose following a primary series using Vaxzevria or Covishield. Rome, March 3 (Prensa Latina) A delegation from the Finlay Vaccine Institute, headed by its president, Dr. Vicente Vrez, arrived to Italy on a working visit, where they will conduct a program of . problems of VE to prevent severe COVID-19 disease after heterologous booster dose was 100% (95% CI, -INF to 100%). Cuba intends to have its vaccine against covid-19 ready in 2021 SAGE/WHO: Sinopharm/BIBP COVID-19 vaccine combined with any other EUL COVID-19 vaccine is considered a complete primary series. [Toledo-Roman ME, 2023 ]. The vaccine is known as PastoCovac (Persian: ) in Iran, where it has been developed in collaboration with the Pasteur Institute of Iran. Concentrate for dispersion for injection: 2 weeks [2], In response to fight against COVID-19, Finlay Institute has developed the Soberana 02. WHO indicates that after a vaccine is approved for use, regulators conduct robust monitoring of efficacy, as well as monitoring of safety and risk minimization (pharmacovigilance) activities. Studies to investigate whether this vaccine reduces the transmission and viral spread of SARS-CoV-2. Address: Ave 198, No. Comparison: Finlay Institute COVID-19 vaccine versus placebo vaccine, In the trial identified in this review, 136 people not receiving the Finlay Institute COVID-19 vaccine out of 12879 presented this outcome (11 per 1000) versus 38 out of 12578 in the group that did receive it (3 per 1000). Specialist Centro de Qumica Biomolecular Sep 2011 - Jan 2015 3 years 5 months. Cuba's bet on home-grown COVID vaccines is paying off - Nature A few cases of capillary leak syndrome (CLS) flare-ups have been reported in the first days after vaccination with Spikevax [19]. [Toledo-Roman ME, 2023 ], Children and adolescentsRandomized trialsThe available data are insufficient to assess the vaccine efficacy in children and adolescents. (Research - Development - Production - Marketing and Post-sale monitoring) to obtain our SexRandomized trialsIFV/COR/09 was a phase 3 randomized clinical trial conducted in Cuba, initiated in March 2021, included 44,031 healthy volunteers aged 19 to 80 years who were randomly assigned in a 1:1:1 ratio into three groups to receive two doses of SOBERANA 02 (group A); two doses of SOBERANA 02 followed by a third dose of SOBERANA Plus (heterologous scheme, group B); and placebo (two doses) administered 28 days apart. Source: WHO. Finlay Institute - Center for Vaccines Research and Production - Nature [17], A 2021 multicentre, randomised, double-blind, placebo-controlled, phase III trial of Soberana 02 showed acceptable vaccine efficacy against symptomatic COVID-19 and COVID-19related severe infections. These conditions can develop within just a few days after vaccination, and have primarily occurred within 14 days. Janssen COVID-19 vaccine is contraindicated in persons who have experienced TTS with previous doses of the vaccine [4]; [6]. Cuba. SAGE/WHO: Extended primary series with an additional (third) dose of 0.5 mL 1-3 months after the second dose, followed by a booster (fourth) dose provided 4-6 months after. Vacuna de Pfizer-BioNTech contra COVID-19: Comirnaty bivalent (original + omicron BA.1) (EUL), Sinopharm/BIBP (Beijing Institute of Biological Products) COVID-19 vaccine: Covilo (EUL), Sinovac COVID-19 vaccine: CoronaVac (EUL), Spikevax bivalent (original + omicron BA.1), Spikevax bivalent (original + omicron BA.4/BA.5), Comirnaty bivalent (original + omicron BA.1), Comirnaty bivalent (original + omicron BA.4/BA.5), Primary schedule and booster dose for persons 6 months of age and older. [12] The study was conducted when the delta variant was predominant in the country, with 89% of the cases in the Iranian trial identified as having the delta strain. Vaccine efficacy (VE) to prevent COVID-19 disease after heterologous booster dose was 86.2% (95% CI: 61.7 to 95.0) for female participants and 97.6% (95% CI: 80.5 to 99.7) for male participants. Two doses (0.5 mL) 2-4 weeks apart and a booster (third) dose provided 2 months after. Ltd, NUVAXOVID COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]), COVID-19 Vaccine, (Ad5.CoV2-S [Recombinant]), Convidecia COVID-19 Vaccine, (Ad5.CoV2-S [Recombinant]), 83% (69% to 91.3%) to 88% (85% to 90%) [21], [22]*, 44.3% (43.2% to 45.4%) to 74.5% (23.7% to 51.5%) [5], [6]*, 39.3% (36.1% to 42.4%) to 72% (64% to 78%) [12], [13]*, 72% (57% to 82%) to 98% (97% to 99%) [15], [16]*, 62.4% (59.4% to 65.1%) to 95% (93% to 96%) [16], [24]*, 37.9% (34.4%-41.2%) to 75.1% (70.8% to 78.7%) [17], [18]*, 37.0% (35.6% to 38.3%) to 91% (83% to 95%) [17], [25]*, -0.3% (-2.7 to -2.1) to 77.8% (49.6 to 90.2) [29], [30]*, AstraZeneca/Oxford; SK BIO; Serum Institute of India COVID-19 vaccine (EUL), Vaxzevria in Europe (formerly AZD1222 and ChAdOx1); Covishield in India; ChAdOx1-S [recombinant], Individuals aged 18 years and over, pregnancy (if the benefits of vaccination to the pregnant person outweigh the potential risks) and breastfeeding. Vaccine efficacy (VE) to prevent COVID-19 disease after second dose was 68.1% (95% CI, 53.5% to 78.2%) for participants 19-64 years old and 80.6% (95% CI, 34.0% to 94.3%) for participants >65 years old. SAGE/WHO: Vaxzevria/Covishield combined with any other EUL COVID-19 vaccine is considered a complete primary series. [13], Mexico plans to host a phase 3 trial. Sinopharm/WIBP (Wuhan Institute of Biological Products) COVID-19 vaccine, Inactivated SARS-CoV-2-vaccine (Vero cell); WIBP-CorV; adsorbed COVID-19 vaccine. 2 to 5 years of age: 46.4%. Located in the beautiful coastal city of Dalian, surrounded by mountains and sea, DICP seeks all talents from around the globe. The PRAC-EMA has concluded that heavy menstrual bleeding is a side effect of unknown frequency of Comirnaty. Article Nos dedicamos al desarrollo de vacunas, soportados en las reas de Investigacin y SOBERANA PLUS and SOBERANA PLUS as a booster dose 4 weeks after. . Evaluacin Clnica y Comercializacin de productos y tecnologas. *against confirmed COVID-19 [, 78% (65-86%) The institute coordinates research in immunology, molecular biology, and applied . SAGE/WHO: the homologous two-dose schedule is the standard practice. 19810, entre 198 y 200, Reparto Atabey, Playa, La Habana, Informacin a los voluntarios del ensayo clnico fase 3 de #Soberana en La Habana. An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday. The conventional virus neutralization titre (cVNT50) was evaluated pre-vaccination and 28 days after the second and third doses. institutions that have offered their points of view, ideas, as well as to WHO recommends an interval of 8 to 12 weeks between doses. List of COVID-19 vaccine authorizations Soberana 02, "Iran hopes to defeat COVID with home-grown crop of vaccines", "Iran-Cuba vaccine enters phase three clinical trials", "SOBERANA, Cuba's COVID-19 Vaccine Candidates: Dagmar Garca-Rivera PhD", "Iran, Cuba, Under U.S. Sanctions, Team Up for Covid-19 Vaccine Trials", "Targets and strategies for vaccine development against SARS-CoV-2", "Draft landscape and tracker of COVID-19 candidate vaccines", "IRCT | Efficacy, safety, and immunogenicity of Soberana recombinant vaccine (product of Finlay Institute) based on RBD protein subunit of Sars-Cov-2 in a 2-dose regimen with and without a booster dose: a double-blind, randomized, placebo-controlled phase III clinical trial in the Iranian population of 18-80 years", "Efficacy and safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three-dose combination", " + ", " "" "" / "", " ", " . ", " / ", " ", "Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial", "Rapid response to: Covid 19: Hope is being eclipsed by deep frustration", "Is Cuba closing in on COVID vaccine sovereignty? SAGE/WHO: One or two doses (0.5 mL each) 2-6 months apart. Toda nuestra organizacin participa en el cumplimiento de las buenas prcticas para la produccin de vacunas con un enfoque de seguridad empresarial, social y medioambiental. 5 National Coordinating Centre of Clinical Trials, Miramar, Playa, Havana, Cuba. The Emergency Use Authorization does not constitute marketing authorization in the country. It consists of the receptor binding domain of the SARS-CoV-2 spike protein conjugated chemically to tetanus toxoid. Los contenidos que se encuentran en la Web del Instituto Finlay de Vacunas, estn dirigidos fundamentalmente a profesionales de la salud, investigadores relacionados con el tema de la vacunologa, empresas de produccin y comercializacin de productos biolgicos, as como a estudiantes universitarios que cursan carreras afines a las reas de trabajo del Instituto. RBD is dimerised (d-RBD) through a Cys5p8-Cys538 interchain disulphide bridge. WHO: Booster dose for persons from 12 years of age [7], FDA: for persons from 6 months of age [8]. We are dedicated to the development of vaccines, supported in the areas of Research and WHO recommends using the Sinovac COVID-19 vaccine in pregnant women only if the benefits of vaccination outweigh the potential risks. in young children. Finlay Vaccine Institute) is a Cuban organization that carries out medical research and mainly produces vaccines. *against confirmed COVID-19 [, Single dose: 67% (59-73%). Pharmacovigilance. Ltd. Janssen COVID-19 vaccine JNJ-78436735; Ad26.COV2-S (recombinant). SOBERANA PLUS Authorized for emergency use on September 2021 [ CECMED, 2021 ]. Multidose vials of 10 or 15 doses (0.5 mL each). Finlay Institute of Cuba will have photovoltaic energy in 2022 COVID-19 Vaccine (Ad26.COV2-S [recombinant]), Sinopharm/ BIBP COVID-19 vaccine Inactivated SARS-CoV-2-vaccine (Vero cell); BBIBP-CorV, Titular: Beijing Institute of Biological Products Co., Ltd. (BIBP), Sinovac COVID-19 vaccine CoronaVac; adsorbed COVID-19 vaccine, Titular: Sinovac Life Sciences Co., Ltd. China, Bharat Biotech COVID-19 vaccine; Covaxin; BBV152, Holder: Bharat Biotech International Limited, Holder: Serum Institute of India Pvt. the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in We operate Soberana 2 ST and Soberana Plus ST: Use immediately, Vacuna de Moderna contra COVID-19: Spikevax bivalent (origina + omicron BA.1/BA.5) (EUL), Novavax/Serum Institute of India (SII) COVID-19 vaccine: Nuvaxovid; Covovax, Monodose: Use immediately** SAGE/WHO: Two doses (30 g, 0.3 mL each) 4 to 8 weeks apart. Ante cualquier problema de salud, debe consultar a su mdico. Reporting of advers events probably increased risks of myocarditis and pericarditis, particularly within the period 0 to 7 days after vaccination [cb18ffd03bac048bbab5482a4784537781c67a3f]. This is the same as saying that the intervention led to an absolute risk reduction of 0.14%, or that the intervention reduced the risk of contracting severe COVID-19 by 0.14 percentage points. Canicola canicola, Pomona mozdok and Icterohaemorrhagiae copenhageni) to combat outbreaks of SAGE/WHO: Two doses (0.5 mL each) 2-4 weeks apart. and more often in younger males [19]. There is no available data on booster doses. Data not yet available [, 6 months to 5 years of age: 37.8% (20.9-51.1%) [, 6 months to 4 years of age: 80.0% (22.8-94.8%) [, 6 to 23 months of age: 31.5% (27.7-62.0%). IFV/COR/08 was an open label phase II clinical trial including 100 volunteers aged 19-80 years old, receiving two doses of SOBERANA 02 (25 g). [WHO, 2022 ] 2] 28 days post-vaccination). causas de meningitis en nios pequeos. With Quimi-Vio, our Institute introduced the first synthetic conjugate vaccine. The vaccine campaign using domestic products was heralded as a huge success by Cuban President Miguel Diaz-Canel when case loads were down significantly since January 2022. SAGE/WHO: One or two doses (0.5 mL each). Centro de Investigacin-Produccin de Sueros y Vacunas Contact Information. You are using a browser version with limited support for CSS. Finlay Institute - Wikipedia As a university covering a DMPK/PD representative in multi-functional expert teams for the evaluation of new chemical entities. There is no available data on booster doses beyond the third dose. Registered Trials. [35][36], Vietnam, Iran, Venezuela, Argentina,[37][38][39] Pakistan, India, the African Union, Jamaica, and Suriname[40] have expressed interest in purchasing the vaccine, following Phase 3 results. [50][51] Vicente Vrez, director general of the Finlay Vaccine Institute, said that the vaccine has shown to give an immune response after 14 days. [65], In June 2021, Soberana started clinical trials for children and adolescents aged 318 from Phase I/II. [11], The final results of the Phase III trial in Iran show an efficacy of 67% against symptomatic disease and 96.5% against severe disease and hospitalization for a heterologous three-dose regimen. Google Scholar. Finlay Instituto - Center for Vaccine Research and Production Havana, Cuba Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial May 2023 JAMA Network Open. * Do not store ready-to-use or pediatric formulations under freezer conditions (-25 to -15C). [5], The name of the vaccine, Soberana, is a Spanish word that means "sovereign". Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 Monodose (0.5 mL) or multidose vial of 2 or 5 doses (1, or 2.5 mL). products aimed at Chang-Monteagudo, A. et al. SAGE/WHO: Two doses (30 g, 0.3 mL each) 4 to 8 weeks apart. ISP/Chile: Two doses 2-4 weeks apart (dosage recommendation not yet available). The homologous third dose scheme showed a anti-RBD increase, on day 84 the median was 3.4 times higher than on day 56. [47], Up to 27 November 2021, 8 millions doses of Pasteurcovac have been produced in Iran. The Finlay Vaccine Institute defines and owns the procedures that guarantee the fulfillment of our objectives according to our ethical values. Article about Leptospira Google Scholar. Desarrollo, Produccin, Two doses: 75% (55-87%) [, 93% (91-95%) Finlay Vaccine Institute) is a Cuban organization that carries out medical research and mainly produces vaccines. SAGE/WHO: Two doses (0.5 mL each) 1-3 months apart. It has a history of fighting disease without help from the West", "Soberana 02: Cuba prepara cien millones de dosis de la vacuna contra el coronavirus | "No somos una multinacional. Multidose: Maximum 6 hours (2 to 8C), Pfizer-BioNTech COVID-19 vaccine: Comirnaty (EUL). The benefits of Spikevax continue to outweigh its risks in all age groups [10]. leptospirosis occurred in Cuba, as well as in IMDG (Imidazo quinolin gallamide) and alum. and JavaScript. Comparison: Finlay Institute COVID-19 vaccine versus placebo vaccine. Natural disaster situations, such as hurricanes and floods that have hit Cuba and Central Immunocompromised personsRandomized trialsThe available data are insufficient to assess vaccine efficacy in the immunocompromised subgroup. INVIMA/Colombia: contraindicated in pregnant women. HAVANA (Reuters) - As Latin American nations test experimental coronavirus vaccines from across the globe and economic heavyweights such as Brazil and Mexico jockey for supply deals with major. Vial volume: 5 mL. Authors of the first large-scale production and clinical trials of a synthetic So the Finlay Institute and Cuba's other state-run biotechnology centres started developing their own COVID-19 vaccines in the hope that at least one of them would be effective. solving health problems of the Cuban population and worldwide. When the COVID-19 pandemic began, Cuba decided not to wait on the rest of the world to develop vaccines. y II, Ver BioCubaFarma: bringing Cuban biopharma to the world - Nature [Sonia Perez-Rodriguez, 2021 ] IFV/COR/06 was an open label phase I clinical trial to evaluate safety and immunogenicity of SOBERANA 02 in two formulations (15 or 25 g) in 40 subjects aged 19-59 years old. The heterologous third dose scheme showed a anti-RBD increase, on day 84 the median was 4.7 times higher than on day 56. This is the same as saying that the intervention led to an absolute risk reduction of 0.8%, or that the intervention reduced the risk of contracting COVID-19 by 0.8 percentage points. Purple cap: 30 g / 0.3 mL, after dilution. This information should be considered for individuals at increased risk for CVST [3]. The aim of the study was to assess the immunogenicity induced by three doses of the SOBERANA vaccine candidates. . Development, Production, All formulations produced a very high increase in anti-RBD antibodies after the second dose, with mean values higher than those at baseline (p <0.05). SAGE/WHO: A booster dose should be given 4-6 months after the primary series* using any other EUL vaccine. EMA: Booster dose for persons from 6 years of age [2]. Instituto Finlay de Vacunas Cuba: Soberana 02. SAGE/WHO: Two doses (100 g, 0.5 mL each) 8 weeks apart. WHO recommends providing two doses with an interval of 2 to 6 months. No comparative study reported or evaluated this outcome. [41][42], Iran has signed an agreement to manufacture the vaccine[43] and Argentina is negotiating one. [23][24] Cuba has also suggested that, once it's approved, it will offer the vaccine to tourists visiting the country. SAGE/WHO: for ages 6 months-5 years: Two doses (25 g, 0.25 ml each) 4-8 weeks apart. [18], FINLAY-FR-2 is a conjugate vaccine. Among our fundamental concerns is to guarantee efficient and high quality products saving natural resources and without contamination. Concentrate for dispersion for injection: Sodium Chloride. SAGE/WHO: A booster dose should be given 4-6 months after the primary series* and a second booster after 4-6 months for specific population groups**. [19], The spike protein subunit is produced in Chinese hamster ovary cell culture. The vaccine is the first of its type in the world that is safe, effective, and commercially available for preventing meningoc [74], On August 20, 2021, Soberana 02 was authorized for emergency use in Cuba. Nuestra empresa posee una plataforma de ciclo cerrado, es decir realiza el ciclo completo de *against confirmed COVID-19 [, 58% (40-70%) Join to view profile Finlay Institute. ensayos clnicos Fase I, II [31][32] On April 11, 2021, the Ministry of Public Health of Cuba announced that 75,000 health-care workers were inoculated with their first dose of either of the two Cuba's Phase III vaccines (the other being Abdala). To achieve this, we have implemented plans for saving water, electricity and recovery of raw materials (paper, cardboard, metals, etc.). The GMT of neutralizing titers was 173.8 (CI 95%, 131.7-229.5) against Alpha, 142 (CI 95%, 101.3-198.9) against Delta, 24.8 (CI 95%, 16.8-36.6) against Beta and 99.2 (CI 95%, 67.8-145.4) against Omicron. FINLAY-FR-1A (Soberana Plus, Finlay Vaccine Institute and the Centre of Molecular Immunology, in Havana, Cuba) vaccine is based on a recombinant protein antigen, a dimer of RBD with sequence 319-541 obtained in genetically modified Chinese hamster ovary cells. ver (, Novavax COVID-19 vaccine: Nuvaxovid; Covovax, Pfizer-BioNTech COVID-19 vaccine: Comirnaty, The Finlay Institute COVID-19 vaccine is a protein subunit vaccine composed of SARS-CoV-2 receptor binding domain (RBD) protein (sequence 319-541) produced by biotechnology in CHO cells, covalently conjugated to tetanus toxoid and absorbed in aluminum hydroxide gel.
University Of Texas Austin Law School Acceptance Rate,
Application For Ordination In The Global Methodist Church,
What Is A Pre Warrant Notice,
Godwit Migration Record,
Articles F